Poxel S.A. (LON:0RA2)

Market Cap	13.20M +4.4%
Revenue (ttm)	6.56M +250.0%
Net Income	-11.71M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,687
Average Volume	15,331
Open	0.3078
Previous Close	0.3010
Day's Range	0.2825 - 0.2850
52-Week Range	0.1760 - 0.8290
Beta	2.32
RSI	50.23
Earnings Date	Mar 24, 2026

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RA2

Financial Performance

In 2024, Poxel's revenue was 6.64 million, an increase of 234.98% compared to the previous year's 1.98 million. Losses were -18.31 million, -47.83% less than in 2023.

Financial numbers in EUR